-

BRBR Investigation: Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of BellRing Brands, Inc. (“BellRing” or the “Company”) (NYSE:BRBR) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

[LEARN MORE ABOUT THE INVESTIGATION]

What Happened?

On May 5, 2025, after market hours, BellRing revealed that starting in Q2 2023, “several key retailers lowered their weeks of supply on hand,” which would create a headwind to Q3 2025 growth. The Company also announced it was expanding promotions to boost sales and “offset [] third quarter reductions in retailer trade inventory levels.” On this news, the price of BellRing shares declined by $13.96 per share, or approximately 18%, from $77.34 per share on May 5, 2025 to close at $63.38 on May 6, 2025.

Then, on August 4, 2025, after market hours, BellRing announced disappointing quarterly consumption of Premier Protein RTD Shakes, which had been expected to outpace shipments by a wider margin given previously announced retailer destocking, but instead came “more in line” with shipments. On this news, the price of BellRing shares declined by $17.46 per share, or approximately 33%, from $53.64 per share on August 4, 2025, to close at $36.18 per share on August 5, 2025.

What Should I Do?

If you purchased or otherwise acquired BellRing securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[LEARN MORE ABOUT SECURITES CLASS ACTIONS]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
investigations@kmllp.com

Kirby McInerney LLP

NYSE:BRBR

Release Versions

Contacts

Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
investigations@kmllp.com

More News From Kirby McInerney LLP

FRMI ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Fermi Inc. Investors

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Fermi Inc. (“Fermi” or the “Company”) (NASDAQ:FRMI) securities during the period of September 28, 2025 through December 11, 2025, inclusive (“the Class Period”). If you suffered a loss on your Fermi investments, you have until March 6, 2026 to request lead plaintiff appointment. For more information: [CONTACT THE FIRM IF YOU SUFFERED A LOSS] Wha...

ARDT Investigation: Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Ardent Health, Inc. (“Ardent” or the “Company”) (NYSE:ARDT) investors concerning the Company's and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On November 12, 2025, Ardent issued a press release announcing its financial results for the third quarter of...

QURE Investigation: Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of uniQure N.V. (“uniQure” or the “Company”) (NASDAQ:QURE) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On November 3, 2025, uniQure disclosed that the Company “believes that the FDA currently no longer agrees that dat...
Back to Newsroom